Vertex Pharmaceuticals received marketing authorization from Health Canada for its treatment of sickle cell disease.

Swiss contract development and manufacturing organization (CDMO) Lonza (VTX: LONN) has signed a long-term commercial supply ...

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...

Basel, Switzerland, 24 September 2024 – Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today the signature of a long-term commercial supply ...

在过去三年中，CRISPR Therapeutics ...

Epigenetic drugs induce heritable modifications to genetic material that result in changes in gene expression without ...

对于传统疗法束手无策的罕见遗传疾病，基因治疗同样也开辟了新的治疗路径。通过基因替代、基因编辑及基因修饰等创新策略，促使人体基因正常表达，以达到治疗效果。基因治疗药物为众多曾被传统疗法束缚的罕见遗传病治疗领域带来了前所未有的希望。

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end ...

Gene and cell therapies bring fresh hope to people with genetic disorders, but recovery can be complex and long-term support ...

After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.